Surface marker analysis of the XL-EDA-ID patient's PBMCs
. | % . | Healthy control, % . |
|---|---|---|
| CD3 | 41.2 | 66.1 ± 5.9 |
| CD4 | 8.0 | 37.7 ± 9.6 |
| CD8 | 31.8 | 23.7 ± 4.2 |
| TCRαβ | 38.0 | 56.5 ± 10.5 |
| TCRγδ | 3.0 | 9.5 ± 5.5 |
| CD4+CD45RA | 1.6 | 32.5 ± 10.8 |
| CD4+CD45RO | 7.2 | 10.2 ± 3.5 |
| CD8+CD45RA | 32.3 | 20.7 ± 5.1 |
| CD8+CD45RO | 9.9 | 7.6 ± 3.6 |
| CD4+CD25+ | 2.2 | 5.5 ± 1.2 |
| CD19 | 32.9 | 23.1 ± 4.1 |
| CD20 | 32.6 | 23.3 ± 4.0 |
| CD19/Sm-IgG | 0.2 | 1.2 ± 1.0 |
| CD19/Sm-IgA | 0.4 | 0.6 ± 0.5 |
| CD19/Sm-IgM | 32.1 | 21.0 ± 3.8 |
| CD19/Sm-IgD | 32.1 | 20.8 ± 3.7 |
| CD16 | 25.0 | 10.5 ± 5.2 |
| CD56 | 24.9 | 9.2 ± 4.8 |
. | % . | Healthy control, % . |
|---|---|---|
| CD3 | 41.2 | 66.1 ± 5.9 |
| CD4 | 8.0 | 37.7 ± 9.6 |
| CD8 | 31.8 | 23.7 ± 4.2 |
| TCRαβ | 38.0 | 56.5 ± 10.5 |
| TCRγδ | 3.0 | 9.5 ± 5.5 |
| CD4+CD45RA | 1.6 | 32.5 ± 10.8 |
| CD4+CD45RO | 7.2 | 10.2 ± 3.5 |
| CD8+CD45RA | 32.3 | 20.7 ± 5.1 |
| CD8+CD45RO | 9.9 | 7.6 ± 3.6 |
| CD4+CD25+ | 2.2 | 5.5 ± 1.2 |
| CD19 | 32.9 | 23.1 ± 4.1 |
| CD20 | 32.6 | 23.3 ± 4.0 |
| CD19/Sm-IgG | 0.2 | 1.2 ± 1.0 |
| CD19/Sm-IgA | 0.4 | 0.6 ± 0.5 |
| CD19/Sm-IgM | 32.1 | 21.0 ± 3.8 |
| CD19/Sm-IgD | 32.1 | 20.8 ± 3.7 |
| CD16 | 25.0 | 10.5 ± 5.2 |
| CD56 | 24.9 | 9.2 ± 4.8 |
Surface markers of the XL-EDA-ID patient PBMCs are shown as a percentage of gated mononuclear cells. Health control values are based on 1- to 6-year-old children for whom informed consent was obtained. Health control values are shown as mean ± SD. Sm indicates surface membrane.